Tomofumi Miura1, Yoshihisa Matsumoto2, Takashi Hama3, Koji Amano4, Yo Tei5, Ayako Kikuchi6, Akihiko Suga7, Takayuki Hisanaga8, Tatsuhiko Ishihara9, Mutsumi Abe10, Keisuke Kaneishi11, Shohei Kawagoe12, Toshiyuki Kuriyama13, Takashi Maeda14, Ichiro Mori15, Nobuhisa Nakajima16, Tomohiro Nishi17, Hiroki Sakurai18, Tatsuya Morita19, Hiroya Kinoshita20. 1. Department of Palliative Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tomiura@east.ncc.go.jp. 2. Department of Palliative Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. yosmatsu@east.ncc.go.jp. 3. Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537-8511, Japan. Japanhamat1971@gmail.com. 4. Department of Palliative Medicine,, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka, 534-0021, Japan. kojiamamo4813@gmail.com. 5. Seirei Hospice, Seirei Mikatahara General Hospital, 3453 Mikatahara-cho, Kita-ku, Hamamatsu City, Shizuoka, 433-8558, Japan. y-jeong680909@ktb.biglobe.ne.jp. 6. Department of Oncology, Mitsubishi Kyoto Hospital, Goshocho 1 Katsura, Nishikyoku, Kyoto, 615-8087, Japan. xxayaccinoxx@gmail.com. 7. Department of Palliative Medicine, Shizuoka Saiseikai General Hospital, 1-1-1 Oshika, Suruga, Shizuoka, 422-8527, Japan. akihikosuga@gmail.com. 8. Tsukuba Medical Center Foundation, 1-3-1 Amakubo, Tsukuba, Ibaraki, 305-8558, Japan. hisanaga@tmch.or.jp. 9. Palliative Care Department, Okayama Saiseikai General Hospital, 1-17-18 Ifukucho, Kita-ku, Okayama City, Okayama, 700-8511, Japan. tishihara@saiseidr.jp. 10. Matsue City Hospital, 32-1 Noshira-cho, Matsue City, Shimane, 690-8509, Japan. abemama@lime.ocn.ne.jp. 11. Department of Palliative Care Unit, JCHO Tokyo Shinjuku Medical Center, 5-1 Tsukudo-cho, Shinjuku, Tokyo, 162-8543, Japan. kankannjp@yahoo.co.jp. 12. Aozora Clinic, 2-357 Midorigaoka, Matsudo City, Chiba, 271-0074, Japan. kawagoe@aozora-clinic.org. 13. Department of Palliative Medicine, Wakayama Medical University Hospital Oncology Center, 811-1 Kimiidera, Wakayama, 641-8509, Japan. kuriyama@wakayama-med.ac.jp. 14. Department of Palliative Care, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. takashi_maeda@hotmail.com. 15. Gratia Hospital Hospice, 6-14-1 Aomadaninishi, Mino, Osaka, 562-8567, Japan. mori.ichi.mail@gmail.com. 16. Department of Palliative Medicine, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aobaku, Sendai, Miyagi, 980-8574, Japan. nakajy@dream.ocn.ne.jp. 17. Kawasaki Comprehensive Care Center, Kawasaki Municipal Ida Hospital, 2-27-1 Ida, Nakahara-ku, Kawasaki, Kanagawa, 211-0035, Japan. ayurveda-pk@hotmail.co.jp. 18. Department of Palliative Care, St. Luke's International Hospital, Tokyo, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. sakurahr2004@gmail.com. 19. Palliative and Supportive Care Division, Seirei Mikatahara General Hospital, 3453 Mikatahara-cho, Kita-ku, Hamamatsu City, Shizuoka, 433-8558, Japan. tmorita@sis.seirei.or.jp. 20. Department of Palliative Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. hikinosh@east.ncc.go.jp.
Abstract
PURPOSE: The Glasgow prognostic score (GPS), which uses C-reactive protein and albumin levels, is a good predictor of prognosis in cancer patients undergoing anti-tumor therapy. The objective of this study was to investigate the correlation between GPS and survival among cancer patients in palliative settings, as findings in such populations have not been well described. METHODS: This was a subanalysis of a multicenter, prospective, cohort study in patients who were adults, diagnosed with advanced cancer, and first referred to palliative care service in Japan. Patients who were not receiving anti-tumor therapy and who had undergone laboratory examinations were eligible. Clinical features were analyzed to investigate prognostic factors. RESULTS: A total of 1160 patients were enrolled (41.6 % female; median age, 72 years). The independent predictors were Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4 (hazard ratio (HR), 1.54), liver metastasis (HR, 1.21), dyspnea (HR, 1.35), edema (HR, 1.25), prognostic performance index (HR, 1.56), neutrophil-lymphocyte ratio (HR, 1.43), and GPS of 2 (HR, 1.36). The sensitivity and specificity for 3-week prognosis of a GPS of 2 were 0.879 and 0.410. Median survival time with GPS of 0, 1, and 2 was 58 days (95 % confidence interval, 48-81), 43 days (37-50), and 21 days (19-24), respectively (log-rank test, p < 0.001). CONCLUSION: The GPS was a good prognostic indicator for cancer patients in palliative settings.
PURPOSE: The Glasgow prognostic score (GPS), which uses C-reactive protein and albumin levels, is a good predictor of prognosis in cancerpatients undergoing anti-tumor therapy. The objective of this study was to investigate the correlation between GPS and survival among cancerpatients in palliative settings, as findings in such populations have not been well described. METHODS: This was a subanalysis of a multicenter, prospective, cohort study in patients who were adults, diagnosed with advanced cancer, and first referred to palliative care service in Japan. Patients who were not receiving anti-tumor therapy and who had undergone laboratory examinations were eligible. Clinical features were analyzed to investigate prognostic factors. RESULTS: A total of 1160 patients were enrolled (41.6 % female; median age, 72 years). The independent predictors were Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4 (hazard ratio (HR), 1.54), liver metastasis (HR, 1.21), dyspnea (HR, 1.35), edema (HR, 1.25), prognostic performance index (HR, 1.56), neutrophil-lymphocyte ratio (HR, 1.43), and GPS of 2 (HR, 1.36). The sensitivity and specificity for 3-week prognosis of a GPS of 2 were 0.879 and 0.410. Median survival time with GPS of 0, 1, and 2 was 58 days (95 % confidence interval, 48-81), 43 days (37-50), and 21 days (19-24), respectively (log-rank test, p < 0.001). CONCLUSION: The GPS was a good prognostic indicator for cancerpatients in palliative settings.
Authors: Francis Lau; Denise Cloutier-Fisher; Craig Kuziemsky; Fraser Black; Michael Downing; Elizabeth Borycki; Francis Ho Journal: J Palliat Care Date: 2007 Impact factor: 2.250
Authors: S Mitsunaga; M Ikeda; S Shimizu; I Ohno; J Furuse; M Inagaki; S Higashi; H Kato; K Terao; A Ochiai Journal: Br J Cancer Date: 2013-04-16 Impact factor: 7.640
Authors: Victoria Louise Reid; Rachael McDonald; Amara Callistus Nwosu; Stephen R Mason; Chris Probert; John E Ellershaw; Séamus Coyle Journal: PLoS One Date: 2017-04-06 Impact factor: 3.240